Categories Cancer Treatment
Relevance: Medium-High
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
Update: New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer
The FDA approved Akeega (niraparib and abiraterone) plus prednisone for the treatment of BRCA-mutated, metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: Women with breast cancer who are considering pregnancy
Study: Pausing hormone therapy to pursue pregnancy does not increase the short-term risk of early-stage cancer recurrence
Women who paused hormone therapy treatment of early-stage hormone receptor-positive (HR-positive) breast cancer to attempt to get pregnant had no increase in short-term recurrence. (Posted 11/3/23)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in certain genes.
Update: New first-line treatment option for metastatic prostate cancer
The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: Gay and bisexual men diagnosed with prostate cancer
Topic: Sexual health concerns of gay and bisexual men with prostate cancer
Prostate cancer therapy can affect gay and bisexual men differently than heterosexual men. Many urologists do not routinely address these unique concerns. Selecting providers who understand the concerns that are unique to gay and bisexual patients and asking questions about sexual health concerns may improve these patients' healthcare experiences. (Posted 9/21/23)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
Update: New drug combination for early treatment of some metastatic prostate cancer
The FDA approved Lynparza (olaparib) for use earlier in treatment of metastatic castration-resistant prostate cancer (mCRPC) when added to abiraterone and prednisone for people with a BRCA mutation found through genetic or tumor testing. Lynparza combined with hormone therapy may now be used as a first-line or later treatment. (Posted 9/11/23)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-Low
Most relevant for: People with solid tumors.
Article: Promising drug for cancer treatment begins clinical trials
Researchers at City of Hope are testing a new type of cancer treatment drug. When tested in animals and cells taken from human cancers, this new drug prevented the growth of many types of cancer. Initial clinical trials in people have just started. (Posted 9/7/23)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with pancreatic cancer who have tumors that can be removed by surgery
Study: Personalized vaccines may help pancreatic cancer treatment
Pancreatic cancer is usually diagnosed at a late stage when patients have few treatment options. Early study results showed that a pancreatic cancer vaccine delayed the return of cancer for nearly half of the participants. (Posted 8/29/23)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with advanced or recurrent endometrial cancer
Study: New treatment option for advanced or recurrent endometrial cancer
If you have advanced or recurrent endometrial cancer, there is a new treatment called Jemperli (dostarlimab) that could be an option for you. This study looked at how well Jemperli worked compared to standard treatment. Based on these results, the Food and Drug Administration (FDA) approved the combination of Jemperli and chemotherapy for certain types of advanced endometrial cancer. (Posted 8/4/23)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People belonging to the LGBTQ+ community
Study: Breast cancer disparities among the LGBTQ+ community
This study looked at differences in breast cancer treatment outcomes among people from the LGBTQ+ community. (Posted 6/28/23)
Este artículo está disponible en español.
READ MORE ›
Relevance: High
Most relevant for: People with HR-positive HER2-negative advanced breast cancer
Study: Breast cancer outcomes improved with CDK4/6 inhibitor treatment
A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)
Este artículo está disponible en español.
READ MORE ›